Omnicare Drugs India Pvt Ltd, a 100 per cent subsidiary of the UAE’s largest pharmaceutical manufacturer Neopharma LLC, and ASKA Pharmaceuticals Co, a top pharma brand in Japan, will jointly set up a manufacturing facility in Visakhapatnam.
The two companies on Thursday announced entering into an agreement to establish a joint venture (JV) in India for the purpose of manufacturing and marketing of pharmaceuticals to global market.
The focus of this state-of-the-art facility, which will come up by 2020 at the cost of Rs 350 crore, will be to manufacture oral solid dosage forms, oral liquids and topical preparations. It will have a peak capacity to manufacture 3 billion tablets a year, said a statement.Neopharma and ASKA Pharma will be taking accreditation from all the major global health regulatory bodies.The manufacturing plant under this JV agreement will be based at JN Pharma City in Andhra Pradesh’s Visakhapatnam. The project will go on floor next month while the operations are likely to start by 2020.
The focus will be to manufacture products targeting chronic therapies in cardiovascular diseases, central nervous system and diabetes along with other drugs from key therapeutic classes targeting Japan and world market.
“The partnership will enable us to transfer skills and knowledge locally,” said B.R. Shetty, Neopharma Founder and Chairman.
N. Suresh Kumar, Neopharma COO, said: “We are entering into a strategic relationship with ASKA Pharmaceuticals to accelerate growth in regulated markets of the US and the European Union and in the emerging markets Africa and Asia.”
Source: Business Standard
UAE based pharmaceutical company, Neopharma obtained its GMP Certification by the National Authority of Medicines and Health Products (Infarmed), Portugal. The certification was granted following an inspection of its Abu Dhabi facility in January 2018, in line with the EU – GMP directives.
The manufacturing plant was found to be GMP Compliant as per the guidelines laid down by the Directive 2003/94/EC. The EU – GMP Certification was accorded to both manufacturing areas within Neopharma (General Products, Beta Lactams).
The approval, which is valid in the entire European Union along with other PICS markets, will facilitate Neopharma’s entry into European markets along with increasing opportunities in contract manufacturing business. Neopharma currently manufactures general products and Beta – Lactams in capsules (hard shelled), tablets and liquid formulations for internal use.
The EU GMP approval comes in line with Neopharma’s commitment towards providing cost effective, high quality pharmaceutical products. In addition to the EU – GMP, the manufacturing facility at Neopharma is also compliant as per UAE MOH GMP guidelines, and ISO certifications including ISO 9001, ISO 14001 and ISO 180001.
UAE based, global pharmaceutical company, Neopharma won the award of ‘Distinguished Pharmaceutical Company’ at the Health Magazine Awards 2018. The annual event, organized by Dubai Health Authority and the HEALTH magazine, aims to acknowledge and appreciate exceptional accomplishments in the field of healthcare. the region’s biggest and most comprehensive annual awards for the healthcare sector brought together more than a thousand healthcare leaders and professionals from the UAE’s private and public sectors.
Winners of the second edition of the Annual Health Awards were awarded at a star-studded gala event at the Grand Hyatt Dubai. Facing stiff competition from the various other big pharmaceutical companies in the region, Neopharma was able to bag the prestigious award due to its many accomplishments over the years. 2017 has been a good year for the Abu Dhabi headquartered organisation. The joint venture with the Japanese SBI Pharmaceuticals brought with itself an innovator molecule which is the latest weapon in the fight against diabetes. Neopharma had also established through various strategic deals, manufacturing facilities around the world, including Japan, Brazil and India.
Team from Neopharma recently participated in the IDF Congress held in Abu Dhabi along with more than 200 diabetes associations to discuss about the trends, treatment, prevention and mitigation of diabetes. The event witnessed high level participation by delegates from diverse backgrounds and nationalities. Speakers from around the world discussed about the prevalence of the non-communicable disease that is, diabetes.
The International Diabetes Federation (IDF) has been leading the global diabetes community since 1950. It is an umbrella organization of over 230 national diabetes associations in 170 countries and territories. The Federation represents the interests of the growing number of people with diabetes and those at risk.
SBI Neopharma has established its footprint in the UAE by opening up an office in Dubai Healthcare City.
SBI Neopharma is a joint venture between SBI Pharmaceuticals Co. Ltd. and Neopharma LLC for the research, production and global sales for medicines, medical devices, cosmetics and health foods utilizing 5-ALA (5-aminolevulinic acid). SBI Pharmaceuticals is part of the SBI Group, a Tokyo based financial services organization with varied business interests.
Dr. BR Shetty, Executive Vice Chairman and Managing Director Neopharma inaugurated the office. He was accompanied by the senior management of the NMC Group that included, Mr. Suresh Kumar, Chief Financial Officer, Mr. Suresh Nandiraju, Chief Operating Officer and Mr. Sumit Bhanot, Marketing Director.
SBI Neopharma’s flagship product NatuALA, contains 5-ALA, a revolutionary novel compound in the treatment of Type 2 Diabetes. NatuALA is currently available in Japan, Bahrain, Jordan and UAE.
Team from Neopharma recently participated at the CPhi Worldwide event in Germany. The event was a huge success for the company and it served as a significant platform for showcasing the company’s wealth of expertise with the global industry stakeholders. The event was attended by a large number of pharmaceutical industry professionals and witnessed several product launches. Neopharma showcased products from more than 10 therapeutic segments at the event.
The UAE’s Ministry of Health and Prevention (Mohap) said it has signed an agreement with Neopharma Factory to provide some medical stocks used for emergency situations.
The list includes 103 types of pharmaceutical products, medicines for emergency cases and other drugs to further boost the health security of the country. Dr Al Amiri said Mohap continuously strengthens its medicine supply by signing agreements with drug manufacturers following the decision of the Council of Ministers No. 39 of 2015.
Dr Amin Hussein Al Amiri, the assistant undersecretary of Public Health Policy and licensing of the Mohap, accompanied by Dr Abdul Karim Abdullah Al Zarouni, the director of the Department of Emergency, Crisis and Disaster Operations, signed the agreement with Suresh Kumar Nandiraju, the chief operating officer of Neopharma.
“The Neopharma agreement is part of our efforts to improve health and medical security, and enable us to immediately respond to emergencies through the acquisition of strategic medical stocks for the ministry’s stores,” he remarked.
“This covers our requirements for one year, including stocks for three months that are readily available in the form of finished goods while the remaining quantity will be in the form of raw materials that will be used in the medicines’ manufacturing process,” he added.
Dr Amin pointed out that the Ministry works towards building quality and safety systems for treatment, health and medicine in accordance with international standards and envisions to promote a healthy society by providing comprehensive and innovative health services.
It implements a regulatory and auditor role in the health sector following an advanced and integrated health legislative system.
Dr Al Zarouni said the agreement sets a mechanism for recycling stocks and constantly offering fresh goods to consumers while maintaining the overall stock quantity required.
The ministry is responsible for storing and maintaining medical stocks according to the global storage and recycling standards, he noted.
“The list comprises a total of 103 drug categories, including 27 for the treatment of infections, 22 for the ear, nose and throat (ENT), 13 for the treatment of respiratory diseases, nine each for cardiovascular and chronic diseases, eight for gastrointestinal diseases, six for the urinary tract, gynecology and obstetrics, four each for blood diseases and malnutrition and bone diseases and one medicine for diseases of the nervous system.
Nandiraju said Neopharma was committed to serving the pharmaceutical manufacturing in the UAE.
“We are honoured to work with the Mohap to provide vital medical supplies that benefit the community during times of crisis, and to allow effective approaches to manage health care costs, increase access to essential medicines and contribute to the strengthening of the pharmacoeconomy in the country,” he added.-TradeArabia News Service
Neopharma, one of the fastest growing pharmaceutical manufacturing company, will be attending the CPhi Worldwide event held at Messe Frankfurt, Germany from October 24-26, 2017. The UAE headquartered company will showcase products from across several therapeutic segments at Stand no 42A25 , Hall No. 4.2
To know more about Neopharma and its therapeutic segments please meet the team at CPhi show or alternatively contact us at firstname.lastname@example.org.
CPhi is a well- established pharmaceutical event known for bringing together the suppliers, distributors and buyers from the pharmaceutical industry. The event hosts exhibitions, conferences, free seminars, awards and pharma community charity expedition across 9 locations worldwide.
Distributors and buyers from the pharma industry across the world gather for the machinery, ingredients, equipment, technology and package and contract service suppliers during CPhi Global events. The event brings together the global communities of pharma professionals and offers opportunities to discover latest trends, ideas and innovations in the pharma industry.
Neopharma, one of the leading pharmaceutical manufacturing companies in the United Arab Emirates (UAE), is planning for a major expansion, primarily in the Middle East and North African (MENA) markets and parts of Asia.
These plans take into account the impending growth of the industry in these markets. The increased push for compulsory health insurance schemes, increased demand of generics and hike in medical tourism numbers would provide a positive push.
“Being one of the largest pharmaceutical markets in the region, MENA’s lure can be attributed to its increasing population, drastically changing healthcare infrastructure and the government’s willingness to radically improve the healthcare systems in the country. Our aim for the region is to help bridge the gap between the patented and the generic by providing products of high quality, which aren’t a burden on the insurance companies,” stated Dr B.R. Shetty, chairman and managing director, Neopharma.
According to reports, the MENA region is forecast to witness an increase in pharmaceutical expenditure to $33.4 billion by the end of 2017, up by nearly $1 billion from the previous year. The Saudi pharmaceutical market accounts for over 60 per cent of the Gulf Cooperation Council (GCC) and is expected to grow at a rate of 9 per cent till 2026, according to separate reports.
“The first phase of expansion would involve proliferation in the other Middle Eastern countries, where Neopharma is aggressively pushing for licences and trademarks. Neopharma’s focus on value-added drugs and not just generics is one of our key differentiators and we aim to add further value to the local health care industry. Furthermore, we have already invested over Dh100 million in setting up a state-of-the-art research and development (R&D) facility,” added Shetty.
Apart from the GCC region, Neopharma has recently made significant investments in a state-of-the-art Japanese factory to the tune of Dh100 million. Additionally, about Dh265 million have been spent on the acquisition of patents and licenses excluding an additional Dh515 million on clinical studies. The Japanese facility will be manufacturing primarily nutraceuticals, one of which has been found effective for Type II diabetic patients and also those in the pre-diabetic stage.
NatuALA, the dietary supplement mentioned earlier is a breakthrough in the management of Type 2 diabetes. The UAE has been reported to have over one million people suffering from diabetes, out of which 450,000 are undiagnosed. The supplement under clinical studies being conducted across the United States, Japan, United Kingdom and Bahrain; could very well provide to be a boon for diabetes patients.
Neopharma has commenced manufacturing NatuALA to address the needs of the ever increasing Type 2 diabetes patients in the GCC region and across the globe under license from SBI Pharma. SBI Neopharma will be distributing the product worldwide.
NatuALA reduces blood glucose levels through an insulin-independent method and keeps fasting glucose levels under critical levels. The dietary supplementary product with 60 patents prevalent in over 35 countries across the globe; utilises a fermentation process to develop it. The process is easily scalable to suit its demands.
If it goes ahead, this would be BR Shetty owned company’s second in the emirate
The Dr. B.R. Shetty-owned Neopharma has confirmed feasibility plans for a second production facility in Abu Dhabi, at an estimated cost of $100 million plus. Additional land has been acquired at the Kizad industrial zone in the emirate, raising the total to 160,000 square metres for both facilities. (Shetty owns a 90 per cent stake in Neopharma.)
It follows Neopharma’s recent acquisition of a pharma factory in Japan, as well as the technical know-how to produce the “NatuALA” pre-diabetes dietary supplement. The company is currently in the midst of clinical trials in the US to get NatuALA approved for the management of Type 2 diabetes.
The health care sector in the UAE has seen a robust deal flow in recent years, with the big operators going in for big-ticket acquisitions to raise hospital bed capacities as well as bring about consolidation among clinics and primary health care providers.
But Neopharma’s push into value-added drugs — and not just of the generic variety — brings about a qualitative change on the pharmaceutical side of the local health care industry. The company is also working on a possible generic drug production facility in Saudi Arabia. Neopharma was set up in 2003.
But it is the know-how from the Japanese acquisition that will come most handy. Once an approval is forthcoming, the NatuALA drug will have extreme potential not just in the US but elsewhere as well, said Shetty. (The company is also pushing the drug’s diagnostic and therapeutic credentials in oncology.) “The “fermentation” technology the Japanese plant uses is a gamechanger and we would like to capitalise on this opportunity,” said Shetty, who is also the founder of NMC Health and currently its joint Non-executive Chairman. “Sure, Neopharma at its launch was primarily manufacturing generic/bulk drugs, but I am now seeing possibilities to do much more.
“We had an offer from Japan’s Cosmo Oil Co. (which owned the pharma company Cosmo ALA) to take over the plant in Japan. We agreed as it was an ideal project with the fermentation technology that we were looking for.”
While Neopharma now owns 100 per cent owner of the plant, it’s Japan exposure also extends to a 65 per cent in Cosmo ALA (now renamed Neo ALA).
The plant was bought for Dh100 million, while Dh265 million was spent on the acquisition of patents and licenses. An additional Dh515 million will go into clinical studies.
Much depends on how quickly the product — NatuALA — is able to make the transition from being an over-the-counter dietary supplement to a full-fledged drug. For this, the US Federal Drug Administration (FDA) needs to give its approval, and thereafter it is just a matter of time before other health authorities do the same.
Approximately one million people in the UAE suffer diabetes and nearly 450,000 are estimated to be undiagnosed cases.
“I don’t think I paid a high premium for the Japanese know-how and manufacturing assets,” said Shetty. “Diabetes, heart-related and cancer are killer diseases and close to 40 per cent in the UAE are diabetic and the numbers are rising.
“NMC Health PLC is listed on the London Stock Exchange and is one of the UAE’s largest private health care providers with over 4 million treated every year. We are proud to be the only company to be so successful on the FTSE 250. It is now trading at 24 (21.86 as of June 30), which is almost a 12-time multiple for investors.
“I currently own 90 per cent in Neopharma and believe that Neopharma will chart an even better strategic route. Neopharma has already started making profits and we want to grow the company further before we decide to get listed. Right now, the year 2020 is the target for getting listed on FTSE.”